文献リスト

1）Sakakibara R, Hattori T, Yasuda K, et al. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci. 1996; 137: 47-56

2）Sakakibara R, Panicker J, Fowler CJ, et al. “Vascular incontinence”: incontinence in the elderly due to ischemic white matter changes. Neurol Int. 2012; 4: e13

3）Andrew J, Nathan PW. Lesions of the anterior frontal lobes and disturbances of micturition and defaecation. Brain. 1964; 87: 233-62

4）Fowler CJ, Griffiths DJ. A decade of functional brain imaging applied to bladder control. Neurourol Urodyn. 2010; 29: 49-55

5）Hentschel F, Damian M, Krumm B, et al. White matter lesions-age-adjusted values for cognitively healthy and demented subjects. Acta Neurol Scand. 2007; 115: 174-80

6）Hanyu H, Shimuzu S, Tanaka Y, et al. Cerebral blood flow patterns in Binswangerʼs disease: a SPECT study using three-dimensional stereotactic surface projections. J Neurol Sci. 2004; 220: 79-84

7）Sakakibara R, Kanda T, Sekido T, et al. Mechanism of bladder dysfunction in idiopathic normal pressure hydrocephalus. Neurourol Urodyn. 2008; 27: 507-10

8）Herzog J, Weiss PH, Assmus A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinsonʼs disease. Brain. 2006; 129: 3366-75

9）Sakakibara R, Tateno F, Kishi M, et al. Pathophysiology of bladder dysfunction in Parkinsonʼs disease. Neurobiol Dis. 2011; 46: 565-71

10）Madhuvrata P, Singh M, Hasafa Z, et al. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012; 62: 816-30

11）Marinkovic SP, Rovner ES, Moldwin RM, et al. The management of overactive bladder syndrome. BMJ. 2012; 344: e2365

12）Sakakibara R, Uchiyama T, Yamanishi T, et al. Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population. Int J Urol. 2008; 15: 778-88

13）Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neuroscience and Therapeutics. 2012; 18: 167-74

14）Sakakibara R, Ogata T, Uchiyama T, et al. How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central AChE inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geri Soc. 2009; 57: 1515-7

15）Traynor K. Mirabegron approved for overactive bladder. Am J Health Syst Pharm. 2012; 69: 1270

16）Andersson KE. Pharmacotherapy of the overactive bladder. Discov Med. 2009; 8: 118-24

17）Kanai A, Zabbarova I, Oefelein M, et al. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in over-active bladders: ICI-RS 2011. Neurourol Urodyn. 2012; 31: 300-8

18）de Groat WC. Influence of central serotonergic mechanisms on lower urinary tract function. Urology. 2002; 59 Suppl 5A: 30-6

19）Ito T, Sakakibara R, Nakazawa K, et al. Effects of electrical stimulation of the raphe area on the micturition reflex in cats. Neuroscience. 2006; 142: 1273-80

20）Sakakibara R, Ito T, Uchiyama T, et al. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. Urol Int. 2008; 81: 335-9

21）Nagasaka Y, Yokoyama O, Komatsu K, et al. Effects of opioid subtypes on detrusor overactivity in rats with cerebral infarction. Int J Urol. 2007; 14: 226-31

22）Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study. Br J Clin Pharmacol. 2006; 61: 456-63

23）Carbone A, Palleschi G, Conte A, Bova G, et al. Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol. 2006; 29: 206-14

24）Marencak J, Cossons NH, Darekar A, et al. Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder. Neurourol Urodyn. 2011; 30: 75-82

25）Guerra LA, Moher D, Sampson M, et al. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. J Urol. 2008; 180: 1091-7

26）Khastgir J, Hamid R, Arya M, et al. Surgical and patient reported outcomes of ʻclamʼ augmentation ileocystoplasty in spinal cord injured patients. Eur Urol. 2003; 43: 263-9

27）Gurung PM, Attar KH, Abdul-Rahman A, et al. Long-term outcomes of augmentation ileocystoplasty in patients with spinal cord injury: a minimum of 10 years of follow-up. BJU Int. 2012; 109: 1236-42

28）Lay AH, Das AK. The role of neuromodulation in patients with neurogenic overactive bladder. Curr Urol Rep. 2012; 13: 343-7

29）Sussman D, Patel V, Del Popolo G, et al. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013; 32: 242-9

30）Choe JH, Choo MS, Lee KS. Symptom change in women with overactive bladder after extracorporeal magnetic stimulation: a prospective trial. Int Urogynecol J Pelvic Floor Dysfunct. 2007; 18: 875-80

31）Yamaguchi C, Sakakibara R, Uchiyama T, et al. Overactive bladder in diabetes: a peripheral or central mechanism? Neurourol Urodyn. 2007; 26: 807-13

32）Mastri AR. Neuropathology of diabetic neuropathic bladder. Ann Intern Med. 1980; 92: 316-8

33）Van Poppel H, Steddens R, Van Damme B, et al. Diabetic cystopathy: neuropathological examination of urinary bladder biopsies. Eur Urol. 1998; 15: 128-31

34）Mitsui T, Kakizaki H, Kobayashi S, et al. Vesicourethral function in diabetic patients: association of abnormal nerve conduction velocity with vesicourethral dysfunction. Neurourol Urodyn. 1999; 18: 639-45

35）Soylu A, Akinci A, Yilmaz R, et al. Sympathetic skin responses in type1 diabetic children: relationship tp urodynamic findings. Neurourol Urodyn. 2006; 25: 243-8

36）Yoshimura N, Chancellor MB, Anderson KE, et al. Recent advances in understanding the biology of associated bladder complications and novel therapy. BJU Int. 2005; 95: 733-8

37）Takahashi O, Sakakibara R, Tsunoyama K, et al. Do sacral/peripheral lesions contribute to detrusor-sphincter dyssynergia? LUTS. 2012; 4: 126-9

38）Sakakibara R, Yamaguchi C, Yamamoto T, et al. Imidapril, an angiotensin-converting enzyme inhibitor, can reverse loss of bladder sensation. J Neurol Neurosurg Psychiatry. 2006; 77: 1100-1

39）Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J. 2009; 85: 552-9

40）Takeda M, Homma Y, Araki I, et al. Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction. BJU Int. 2011; 108: 100-7

41）Sakakibara R, Uchiyama T, Asahina M, et al. Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin Auton Res. 2003; 13: 51-3

42）Yamanishi T, Yasuda K, Kamai T, et al. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol. 2004; 11: 88-96

43）Barendrecht MM, Oelke M, Laguna MP, et al. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int. 2007; 99: 749-52

44）Yamamoto T, Sakakibara R, Yamanaka Y, et al. Pyridostigmine in autonomic failure: can we treat postural hypotension and bladder dysfunction with one drug? Clin Auton Res. 2006; 16: 296-8

45）Yamamoto T, Sakakibara R, Uchiyama T, et al. Neurological diseases that cause detrusor hyperactivity with impaired contractile function. Neurourol Urodyn. 2006; 25: 356-60

46）Ito T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention in multiple system atrophy: when does it occur and how do we manage it? Mov Disord. 2006; 21: 816-23

47）Sakakibara R, Uchiyama T, Yamanishi T, et al. Sphincter EMG as a diagnostic tool in autonomic disorders. Clin Auton Res. 2009; 19: 20-31

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp